

Data supplement

Table DS1 Baseline demographic data for the two groups

	Clozapine group (<i>n</i> = 80)	Chlorpromazine group (<i>n</i> = 80)	<i>P</i>
Gender: male/female	43/37	41/39	0.87
Age at onset of psychosis, years: ^a mean (s.d.)	27.1 (6.1)	27.2 (6.8)	0.86
Duration of untreated psychosis, months: ^a mean (s.d.)	17.7 (16.7)	19.7 (19.0)	0.49
Age at admission, years: mean (s.d.)	28.5 (6.5)	28.7 (7.2)	0.85
Baseline Brief Psychiatric Rating Scale score, mean (s.d.)	43.3 (5.1)	44.4 (5.1)	0.14

a. *n* = 79 for the chlorpromazine group.

Table DS2 Baseline demographic data for the 29 participants who remained on the medication to which they were originally assigned for the entire 9-year study period and the 95 participants who remained in the study but switched medications

	Remained on original medication (<i>n</i> = 29)	Switched medication during study (<i>n</i> = 95)	<i>P</i>
Gender: male/female	19/10	46/49	0.14
Age at onset of psychosis, years: mean (s.d.)	26.9 (6.6)	26.8 (6.6)	0.97
Duration of untreated psychosis, months: mean (s.d.)	16.8 (19.2)	19.7 (17.5)	0.47
Age at admission, years: mean (s.d.)	28.2 (7.2)	28.4 (7.0)	0.90
Baseline Brief Psychiatric Rating Scale score, mean (s.d.)	43.4 (4.2)	44.0 (5.3)	0.51